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Abstract
Oily fish and other sources of long-chain n-3 polyunsaturated fatty acids (n-3 LCPs) have been proposed as protective against dementia and
age related cognitive impairment. The basic mechanisms underlying these proposed benefits have been postulated and experimental
studies supporting the plausibility of the putative effects have been published. Observational epidemiological and case control studies
also largely support a protective role of fish consumption on cognitive function with advancing age, albeit with important unexplained
heterogeneity in findings. In this review we report the findings of the latest Cochrane review on the benefits of n-3 LCP supplementation
on cognitive function among cognitively healthy older people and expand the review by including trials conducted with individuals with
prevalent poor cognitive function or dementia. We identified seven relevant trials, four among cognitively healthy older people, and three
among individuals with pre-existing cognitive decline or dementia, and overall conclude that there is no evidence to support the routine
use of n-3 LCPs supplements for the prevention, or amelioration, of cognitive decline in later life. We identified several challenges in the
design of intervention studies for the prevention of dementia and cognitive decline in older people that require careful consideration
especially in recruitment and retention in long-term trials. Whether the lack of agreement in findings from mechanistic and observational
data and from intervention studies reflects a real absence of benefit on cognitive function from n-3 LCP supplementation, or whether it
reflects intrinsic limitations in the design of published studies remains open to question.
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Numerous reviews of findings from animal research as well as
biological, clinical and epidemiological data underscore a pro-
tective role of dietary intake of n-3 (or omega-3) long-chain
polyunsaturated fatty acids (n-3 LCPs) on dementia, including
Alzheimer’s disease (AD). Various mechanisms of action have
been proposed including improvement of cerebral blood
flow, maintenance of the structural integrity of neuronal mem-
branes, and reduction in amyloid-ß pathology(1–7). The bal-
ance of evidence from prospective studies suggests that n-3
LCPs may have a greater role in slowing or delaying cognitive
decline among healthy older people than in the treatment of
individuals with dementia(2,3,6,7). The brain is particularly
rich in n-3 LCPs and several mechanisms have been postulated
for their potential protective actions. First, docosahexaenoic
acid (DHA) is a component of membrane phospholipids in
the brain and adequate n-3 LCP status contributes to
specific neural membrane structural properties and functions
including ion transport, signal transduction, synapsis for-
mation, neurotransmitter release and reuptake. DHA also
contributes to sequestering free radicals and preventing
amplification of oxidative damage. Secondly, eicosanoids
and docosanoids produced by cyclo- and lipo-oxygenase
action on long-chain polyunsaturated fatty acids act as cellular
mediators of inflammation, allergy and immunity, oxidative
damage, vascular responses and thrombosis and may thereby
influence risk especially of vascular dementia(8).
Evidence from cross-sectional analyses involving dietary
fish and/or supplemental n-3 LCP intake, as well as findings
based on plasma eicosapentaenoic acid (EPA) and DHA con-
centrations are equivocal. For example, some epidemiological
studies document dose-response protective asssociations of
n-3 LCPs on the cognitive performance of older individuals
in different countries(9,10), with the associations applying to
various cognitive domains(10), whereas other similarly desig-
ned studies report no associations in adjusted models(11,12).
Regarding plasma n-3 LCP concentrations, case-control(13)
and prospective studies with older individuals free of demen-
tia at baseline report significant inverse associations between
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the concentrations of these nutrients and risk of cognitive
decline or incident dementia(14,15). However, other studies
have documented elevated EPA concentrations among cogni-
tively impaired older individuals, and elevated DHA, n-3
fatty acids, and total long-chain polyunsaturated fatty acids
concentrations have been observed among individuals with
dementia(16).
Population-based longitudinal analyses of data from older
individuals who were cognitively healthy at baseline generally
showan inverse association betweenfish consumption and inci-
dent dementia(17–19), albeit with some exceptions(12,20). Some-
what less consistency exists among the research findings
regarding the types of n-3 LCPs purporting the strongest benefit.
Some prospective epidemiological studies show both EPA and
DHA to be protective against cognitive decline(19), whereas
others report associations either with DHA(18) or EPA(21).
A comprehensive review of 27 prospective studies of fish or
n-3 LCPs in diet or blood, and 9 cross-sectional studies of n-3
LCPs in plasma, erythrocytes, or in the diet suggested that the
lack of consistency in the findings could be attributed to dis-
parate study designs and populations, inadequate statistical
adjustment, and differences in predictor/outcome assessment
methodology(3). Authors have also highlighted that fish
intake is not equivalent to n-3 LCP intake and that the genetic
heterogeneity among different populations with respect to
both n-3 fatty acids metabolism and dementia susceptibility
might weaken the benefits of these nutrients(2).
A Cochrane review of the evidence from randomised con-
trolled trials found no trials published before October 2005
investigating the effects of n-3 polyunsaturated fatty acid sup-
plementation on cognitive function among cognitively healthy
older people(22). We here present findings from the recently
updated Cochrane review(23) of the effect of n-3 poly-
unsaturated fatty acid supplementation on the prevention of
dementia and cognitive decline among cognitively healthy
older people and expand the scope of the review to include
randomised controlled trials conducted among individuals
with prevalent poor cognitive function or dementia.
Methods
For a Cochrane review update(23), the major healthcare data-
bases (Medline, Embase, Cinahl, Psycinfo and Lilacs) and trial
registers (International Standard Randomised Controlled Trial
Number, ClinicalTrials.gov and The Cochrane Library’s Central
Register of Controlled Trials) were systematically searched up
to April 2012. Search terms included variants and combinations
of: fatty acids, omega-3, polyunsaturated fatty acid, unsaturated
fatty acid, essential fatty acid, eicosapentaenoic acid, docosa-
hexaenoic acid, docosapentaenoic acid, alpha-linolenic acid,
fish oil, n-3 fatty acid, long chain fatty acids, primrose oil, linseed
oil, oily fish, flaxseed oil, randomized controlled trial, controlled
clinical trial, healthy old or elderly or aged or senior, healthy per-
sons, cognition, dementia.
For the Cochrane review update(23), randomised controlled
trials involving individuals over 60 years of age were included
if they also had the following characteristics. First, they pre-
screened participants for dementia and excluded individuals
with pre-existing dementia. Second, they pre-screened partici-
pants for cognitive impairments and excluded individuals with
pre-existing cognitive impairment. Third, the intervention
period was a minimum duration of 26 weeks (180 days).
In this review we expand the inclusion criteria for studies
and participants to include randomised controlled trials that
did not screen or exclude individuals with possible cognitive
decline or with existing cognitive impairment or dementia.
We chose to include any n-3 polyunsaturated fatty acid inter-
vention (including mixtures of n-3 fatty acids) that involved
dietary supplementation or provided meals, versus placebo
or usual diet. Our primary outcome of interest was incidence
of dementia, our secondary outcome was cognitive decline
defined as change in a relevant cognitive function over the
intervention period.
Results
Our systematic search process identified 7 relevant studies for
this review (Table 1). Three studies (included in the Cochrane
review) enrolled only cognitively healthy older people(24–26),
one study enrolled apparently cognitively normal older
people but did not screen for cognitive function at base-
line(27), one study enrolled participants with age-related cogni-
tive decline(28) and two studies enrolled participants with mild
to moderate AD(29,30). All studies were conducted in high-
income countries, sample sizes ranged from 204 to 4837 and
study duration ranged from 24 weeks to 4 years. Of the ident-
ified trials, six provided interventions as daily capsules con-
taining varying mixtures of EPA and DHA with overall doses
up to 2 g per day. One trial provided fortified margarines con-
taining EPA, DHA and alpha-linolenic acid (ALA)(25). None of
the identified trials provided information on the incidence of
dementia. Change in cognitive outcome was assessed using
a variety of measures (Table 2) and study findings are pre-
sented below in narrative format.
Trials in cognitively healthy older populations
In a study from the Netherlands, a total of 302 cognitively
healthy older people aged $65 years were randomised into
a low-dose treatment group (400 mg EPA þ DHA daily), a
high-dose treatment group (1800 mg EPA þ DHA daily), or
placebo (sunflower oil) for 26 weeks. Cognitive function
was evaluated at baseline and follow-up with a large battery
of cognitive tests assessing memory, executive function, atten-
tion and sensorimotor speed. An analysis of variance showed
no significant differences between the groups in cognitive
tests scores at the end of the study(26).
In the OPAL study a total of 867 cognitively healthy adults
aged 70–79 years were randomised into an active group
(200 mg EPA þ 500 mg DHA daily) or placebo (olive oil) for
24 months. Cognitive function was evaluated at baseline and
follow-up with a battery of cognitive tests, including the Cali-
fornia Verbal Learning Test (CVLT) as the primary outcome. A
total of 748 participants completed the study. Intention-to-treat
analysis of covariance models showed no change over the
course of the intervention in CVLT or any secondary cognitive
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outcomes(24), secondary analysis revealed interaction between
specific genetic polymorphisms in fatty-acid desaturase genes
and lipid transport proteins and the response to the interven-
tion (in preparation).
A secondary outcome paper from the Alpha Omega
Trial(31), reported the impact of four margarine varieties
(daily intake of margarine supplemented with 400 mg
EPA þ DHA in a 3:2 ratio, margarine supplemented with 2 g
ALA, margarine supplemented with 400 mg EPA þ DHA and
2 g ALA, or placebo margarine) for 40 months on 4837 older
people aged 60–80 years with a history of myocardial
infarction. Cognitive function data were collected on 2911 of
the randomised individuals. Rates of change in cognitive func-
tion, assessed using the Mini-Mental State Examination
(MMSE), did not differ between trial arms over the course of
the study(25).
The SU.FOL.OM3 trial randomised 2501 individuals with a
history of cardiovascular disease. Of the randomised individ-
uals, 1748 had complete cognitive assessment data, 858 of
whom were aged .60 years and are included in this
review. There was no formal screening of participants for cog-
nitive function at the start of the study. Participants were ran-
domised in a 2 £ 2 factorial design to one of four groups:
0·56 gm folate þ3 mg vitamin B6 þ 0·02 mg vitamin B12; or
600 mg EPA þ DHA in a 2:1 ratio; or B vitamins and n-3
LCPs combined; or placebo (liquid paraffinþ fish oil).
Cognitive function after 4 years of supplementation was
assessed with the French version of the modified Telephone
Interview for Cognitive Status. Analysis of covariance and
multiple logistic regression showed no significant effects of
group assignment on cognitive function(27).
Trials among older populations with evidence of cognitive
impairment
In a study from Sweden, 204 adults (mean age ¼ 74 y) with mild
to moderate AD were randomised to an active group (1700 mg
DHA þ 600 mg EPA daily) or placebo (corn oil including 0.6g
linoleic acid) for 6 months. After 6 months, all participants
received the n-3 LCP supplementation for an additional 6
months. Cognitive function was assessed with the MMSE, the
cognitive subscale of the Alzheimer’s Disease Assessment
Scale and the Clinical Dementia Rating scale. A total of 174 par-
ticipants completed the trial. At 6 months, repeated-measures
analysis of variance showed that the decline in cognitive func-
tions did not differ between the groups. However, in a subgroup
(n ¼ 32) with very mild cognitive dysfunction at baseline, stat-
istically significant positive effects of the supplementation on
MMSE scores were observed(29).
In the MIDAS trial, 485 individuals aged $55 years with
defined age-related cognitive decline were randomised into
an active group (900 mg DHA daily) or placebo (corn oil þ
soy oil) for 24 weeks. The primary outcome was the
CANTAB Paired Associate Learning (PAL) and adjusted
Table 1. General characteristics of randomised controlled trials included in review
First author, study location Study population Interventions Duration (months)
Andreeva, France(27) Subsample of 858 adults aged .60 years Active
600mg EPA þ DHA daily
Placebo
liquid paraffin þ fish oil þ B vitamins
48
Dangour, England and Wales(24) 867 adults aged 70–79 years.
Key exclusion: poor cognitive health
(Mini-Mental State
Examination [MMSE] ,24)
Active
200mg EPA þ 500mg DHA daily
Placebo
olive oil
24
Freund-Levi, Sweden(29) 204 adults with mean age 74 years
and mild to moderate Alzheimer’s
Disease (MMSE $15)
Active
1·7g DHA þ 0·6g EPA daily
Placebo
corn oil including 0.6g linoleic acid
6
Geleijnse, The Netherlands(25) 2911 adults aged 60–80 years with
history of myocardial infarction.
Key exclusion: poor cognitive health
(MMSE ,21)
Active
margarines containing
a. 400mg EPA/DHA daily
b. 2g ALA daily
c. 400mg EPA/DHA þ 2g ALA daily
Placebo
Margarine
40
Quinn, USA(30) 402 adults with mean age 76 years
and mild to moderate Alzheimer’s
Disease (MMSE ¼ 14–26)
Active
2g algal DHA daily
Placebo
corn or soy oil
18
Van de Rest, The Netherlands(26) 302 adults aged $65 years.
Key exclusion: poor cognitive
health (MMSE , 21)
Active
a. 1800mg EPA þ DHA daily
b. 400mg EPA þ DHA daily
Placebo
high-oleic sunflower oil
6
Yurko-Mauro, USA(28) 485 adults aged $55 years with age-related
cognitive decline and #28 on logical memory
immediate recall or #15 on delayed
recall, and MMSE $ 26
Active
900mg DHA daily
Placebo
corn oil þ soy oil
6
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Table 2. Primary cognitive test results from randomised controlled trials included in review
First author Intention to treat sample Primary cognitive outcome measure Baseline scorea Final scorea
Andreeva et al.(27) Active
420
Placebo
438
Telephone Interview for Cognitive Status,
modified French version
Not collected Active
27·2 (4·9)
Placebo
27·3 (5·1)
Dangour et al.(24) Active
375
Placebo
369
California Verbal Learning
Test immediate recall (sum of 3 trials)
Active
24·1 (6·0)
Placebo
23·9 (5·7)
Active
24·1 (6·7)
Placebo
24·4 (6·4)
Freund-Levi et al.(29) Active
103
Placebo
101
Mini-Mental State
Examination (MMSE)
Alzheimer’s Disease
Assessment Scale (ADAS-Cog)
Active
MMSE: 23·6 (22·8, 24·4)b
ADAS-Cog: 25·7 (23·6, 27·8)b
Placebo
MMSE: 23·2 (22·4, 24·0)b
ADAS-Cog: 27·2 (25·1, 29·4)b
Active
MMSE: 22·1 (21·1, 23·1)b
ADAS-Cog: 31·2 (28·3, 34·2)b
Placebo
MMSE: 21·9 (20·8, 22·9)b
ADAS-Cog: 32·8 (29·8, 35·9)b
Geleijnse et al.(25) Active
1,240
Placebo
1,282
MMSE Active and placebo
28·3 (1·6)
Active
a. Change: 20·78 (2·32)
b. Change: 20·67 (2·24)
c. Change: 20·53 (2·07)
Placebo
Change: 20·71 (2·36)
Quinn et al.(30) Active
238
Placebo
164
ADAS-Cog
Clinical Dementia Rating
(CDR) sum of boxes
Active
ADAS-Cog: 23·77 (8·9)
CDR: 5·61 (2·62)
Placebo
ADAS-Cog: 23·96 (9·2)
CDR: 5·77 (2·61)
Active
ADAS-Cog change: 7·98
CDR change: 2·87
Placebo
ADAS-Cog change: 8·27
CDR change: 2·93
Van de Rest et al.(26) Active high dose
96
Active low dose
100
Placebo
106
Word Learning Test (WLT)
immediate recall (sum of 5 trials)
Active high dose
39·3 (8·8)
Active low dose
40·8 (8·6)
Placebo
39·6 (9·7)
Active high dose
44·9 (9·9)
Active low dose
46·1 (10·1)
Placebo
44·8 (9·4)
Yurko-Mauro et al.(28) Active
242
Placebo
243
CANTAB Paired Associate
Learning (PAL) test
Active
13·4 (11·6)
Placebo
12·1 (10·9)
Active
8·8 (9·9)
Placebo
9·7 (10·4)
a Values are mean (SD) unless stated.
b Mean (95% confidence interval).
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ANCOVA showed that treatment was associated with signifi-
cantly fewer PAL 6 pattern stage errors(28).
Finally, the Alzheimer’s Disease Cooperative Study random-
ised 402 individuals (mean age ¼ 76 y) with mild to moderate
AD into an active group (2000 mg DHA daily) or placebo (corn
or soy oil) for 18 months. Cognitive function was assessed
with the cognitive subscale of the Alzheimer’s Disease Assess-
ment Scale and the Clinical Dementia Rating sum of boxes.
A total of 295 participants completed the trial and
analysis did not identify any evidence that compared to the
placebo, DHA slowed the rate of cognitive decline in these
participants(30).
Discussion
Several mechanisms have been postulated for the possible
protective role of n-3 LCPs in cognitive decline and dementia.
Experimental animal studies using a mouse model of AD have
shown that dietary DHA deficiency induces a decline in DHA
content of the frontal cortex which is significantly associated
with loss of dendritic spine formation, increases oxidative
damage and affects the hippocampus impairing memory
acquisition, while supplementation with DHA increases n-3
LCP content of the brain, protects against adverse biochemical
effects of deficiency, and results in improved cognitive per-
formance(32). DHA also modulates expression of genes related
to neurogenesis(33) and is directly involved in protection of the
ageing brain from hypoxic injury through docosanoid-related
mechanisms(34,35).
The recent United Nations Food and Agriculture Organis-
ation consultation on fats and fatty acids in human nutrition
recommended an n-3 LCP (EPA þ DHA) intake for adults of
250 mg per day and stated that this may contribute to the pre-
vention of cardiovascular disease(36). The significant role of
n-3 LCPs for brain health was acknowledged but no rec-
ommendations were established for older people based on
this role because the data on specific functional outcomes
were considered insufficient. The average dietary intake of
preformed DHA in European adults consuming omnivorous
diets is about 150–200 mg per day although intake levels in
much of the rest of the world are far lower(37).
For this review we identified seven trials that investigated
the effect of n-3 LCP supplementation on cognitive function
in older people. Four of these trials were among cognitively
healthy (or presumptively cognitive healthy) older
people(24–27), and none of these trials identified any benefit
from n-3 LCP supplementation. A further three trials enrolled
older people with cognitive function impairments ranging
from defined age-related cognitive decline to moderate AD.
One of these three trials identified some evidence of a benefit
from DHA supplementation(28), the other two trials did not
support this finding(29,30). Overall, the evidence from trials of
n-3 LCP supplementation among cognitively healthy and cog-
nitively impaired older people does not support the use of n-3
LCPs for the prevention of cognitive decline.
The strength of the epidemiologic associations and the pro-
posed mechanisms underlying the effects of n-3 LCPs on brain
function are increasing, and yet of seven trials included in our
review, only one identified any potential benefits from n-3
LCP supplementation on cognitive function. This discrepancy
between epidemiological associations and trial evidence is not
unique to n-3 LCPs(38) although there may also be some
unique challenges in the design of long-term intervention
studies for the prevention of dementia and cognitive decline
in older people.
From the standpoint of determining the primary health
effectiveness of interventions, a key concern relates to the
recruitment of samples of older people that match the
health and demographic characteristics of the target popu-
lation(39). Recruitment procedures (including the use of
extensive exclusion criteria) favour the selection of healthier
participants, and participants who are more motivated and
adherent to instructions tend to be healthier, consume a
better diet and are more active. Physical activity and food
consumption patterns may have an effect on disease pro-
gression that is separate from the effect of the intervention
under investigation.
Retention of participants in long-term studies of cognitive
function is also a concern since individuals who drop out of
trials frequently have different demographic and health
characteristics from those who remain active until the end of
the trial. In the four trials that recruited cognitive healthy
(or presumptively cognitive healthy) adults, the percentage
of participants with data available for the final trial analyses
varied from between 62 % in a trial of 40 month duration(25)
to 99 % in a trial of 6 month duration(26). In the OPAL trial
(24 month duration), retention was 86 %, and those individuals
who withdrew had poorer cognitive function at the start of the
study than those who remained in the study(24). Similarly, in
the SU.FOL.OM3 trial (48 month duration), retention was
75 % and individuals who completed the trial had higher
EPA and DHA concentrations and had slightly higher verbal
fluency at baseline(27). As expected, longer trials had lower
overall retention and the evidence also suggests that those
participants who drop out of trials are potentially exactly
those who might benefit most from n-3 LCP supplementation.
From the perspective of identifying a suitable intervention
to maintain cognitive function into later life, the current evi-
dence base is disappointing. Whether this lack of evidence
results from insufficient thought into designing studies of
appropriate size and duration, or whether it relates to the
selection of study populations who may benefit most from
n-3 supplementation, such as those with low n-3 LCP status
at study entry, or finally whether it suggests that despite the
epidemiological and mechanistic evidence n-3 LCP sup-
plementation does not affect cognitive function, remains
open to question.
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